Axsome Therapeutics (AXSM) PT Raised to $31 at Ladenburg Thalmann

July 26, 2017 6:48 AM EDT
Get Alerts AXSM Hot Sheet
Price: $76.90 +6.85%

Rating Summary:
    13 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 2 | Down: 23 | New: 24
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Ladenburg Thalmann raised its price target on Axsome Therapeutics (NASDAQ: AXSM) to $31.00 (from $28.00) while maintaining a Buy rating.

Analyst Matt Kaplan comments "Interim Phase 3 data for CRPS is expected in 4Q17, with AXS-02 potentially being initially launched in the US in 2019, and other indications following in later years. We estimate AXS-02 can achieve $150 million in revenue in CRPS, with other pain indications also adding materially. At peak, we estimate AXS-02 can reach $600 million."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Comments

Related Entities

Ladenburg Thalmann Financial Services